title: A novel experimental model of acute hypertriglyceridemia induced by schisandrin B.
abstract: Mice were intragastrically treated with single doses (0.05-0.8 g/kg) of schisandrin B (a dibenzocyclooctadiene derivative isolated from the fruit of Schisandra chinensis). Twenty-four hours after schisandrin B administration, the serum triglyceride level was increased by 10-235% in a dose-dependent manner. However, the serum low density lipoprotein cholesterol level was significantly decreased by 28% at a dose of 0.8 g/kg. When given once daily (0.01-0.2 g/kg) for 4 days, schisandrin B also dose-dependently elevated the serum triglyceride level (17-134%). Kinetics parameters estimated by Scott's plot analysis of schisandrin B-induced changes in serum and hepatic triglyceride levels were determined: serum-E(max) (maximal effect)=6 mmol/L (384% increase, P<0.001); K(D) (affinity)=0.59 mmol/kg; pD(2) (an index of affinity)=6.62; liver-E(max)=21 micromol/g (68% increase, P<0.001); K(D)=0.37 mmol/kg; pD(2)=6.83. The efficacy of schisandrin B in increasing the triglyceride level was 5.6-fold higher in serum than in liver tissue. Fenofibrate (0.2g/kg) treatment, when in combination with schisandrin B (0.2g/kg), for 4 days significantly reduced the schisandrin B-induced increase in serum triglyceride level (by 81%, P<0.001). Hepatic triglyceride level was also decreased (by 100%, P<0.001) by co-treatment with fenofibrate. Our results suggest that schisandrin B treatment can be used to establish a mouse model of acute hypertrigylceridemia.
authors.affiliation: Department of Pharmacology, Beijing University of Chinese Medicine, Beijing 100102, China. si-yuan-pan@163.com
authors.forename: Si-Yuan
authors.initials: SY
authors.lastname: Pan
authors.forename: Hang
authors.initials: H
authors.lastname: Dong
authors.forename: Yi-Fan
authors.initials: YF
authors.lastname: Han
authors.forename: Wen-Yuan
authors.initials: WY
authors.lastname: Li
authors.forename: Xing-Ye
authors.initials: XY
authors.lastname: Zhao
authors.forename: Kam-Ming
authors.initials: KM
authors.lastname: Ko
mesh_terms: D000818:Animals; D034242:Cyclooctanes / Q000494:pharmacology; D004195:Disease Models, Animal; D011345:Fenofibrate / Q000494:pharmacology; D015228:Hypertriglyceridemia / Q000139:chemically induced*; D000960:Hypolipidemic Agents / Q000494:pharmacology; D017705:Lignans / Q000494:pharmacology*; D008055:Lipids / Q000032:analysis / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D011083:Polycyclic Compounds / Q000494:pharmacology*
chemical_list: D034242:Cyclooctanes; D000960:Hypolipidemic Agents; D017705:Lignans; D008055:Lipids; D011083:Polycyclic Compounds; C015499:schizandrin B; D011345:Fenofibrate